(Q36531901)

14 August 2017

1 reference

title

Differences in phenytoin biotransformation and susceptibility to congenital malformations: a review (English)

1 reference

14 August 2017

Differences in Phenytoin Biotransformation and Susceptibility to Congenital Malformations: A Review (English)

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

28 October 2022

0 references

1 reference

D. C. Van Dyke

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1683079

28 October 2022

M. J. Berg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1683079

28 October 2022

C. H. Olson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1683079

28 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1683079

28 October 2022

publication date

1 September 1991

1 reference

full work available at URL

14 August 2017

http://journals.sagepub.com/doi/pdf/10.1177/106002809102500914

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

DICP : the annals of pharmacotherapy

28 October 2022

published in

1 reference

14 August 2017

volume

25

1 reference

14 August 2017

issue

9

1 reference

14 August 2017

page(s)

987-992

1 reference

Teratogen update: clinical aspects of thalidomide embryopathy--a continuing preoccupation.

14 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

[Thalidomide embryopathy. II. Results of individual anamnestic findings in the areas of inquiry of the universities of Bonn, Cologne, Muenster and Duesseldorf pediatric clinics]

28 October 2022

2

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Teratogenicity of anticonvulsant drugs. I: Review of the literature

28 October 2022

4

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Teratogen update: fetal hydantoin effects

28 October 2022

5

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

28 October 2022

6

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver

28 October 2022

8

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation

28 October 2022

9

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus

28 October 2022

10

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

The fetal hydantoin syndrome

28 October 2022

11

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome

28 October 2022

12

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Infants exposed in utero to antiepileptic drugs. A prospective study.

28 October 2022

13

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan

28 October 2022

14

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Family studies in fetal phenytoin exposure

28 October 2022

16

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Discordant expression of fetal hydantoin syndrome in heteropaternal dizygotic twins

28 October 2022

17

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Predisposition to phenytoin hepatotoxicity assessed in vitro

28 October 2022

18

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Genetic predisposition to phenytoin-induced birth defects

28 October 2022

19

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

The fetal hydantoin syndrome: answers from a mouse model.

28 October 2022

20

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Variable patterns of malformation in the mouse fetal hydantoin syndrome

28 October 2022

22

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Phenytoin teratogenicity in the primary and secondary mouse embryonic palate is influenced by the H-2 histocompatibility locus.

28 October 2022

23

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Susceptibility to phenytoin-induced cleft palate in mice is influenced by genes linked to H-2 and H-3.

28 October 2022

24

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Phenytoin binding in healthy volunteers

28 October 2022

27

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Glutathione transferases--structure and catalytic activity

28 October 2022

29

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Drug Metabolism and Disposition

28 October 2022

31

13

382

Rane A

1985

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Phenytoin-folic acid: a review.

28 October 2022

32

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Utilization of Km for phenytoin dosage after folate addition to patient regimen

28 October 2022

33

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Human liver glutathione S-transferases: complete primary sequence of an Ha subunit cDNA

28 October 2022

36

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Research Communications in Chemical Pathology and Pharmacology

28 October 2022

37

59

173

Roy D

1988

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-amino P.G.A) administered by the oral route

28 October 2022

38

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Mental effects of anticonvulsants, and folic acid metabolism

28 October 2022

40

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Further experience of vitamin supplementation for prevention of neural tube defect recurrences

28 October 2022

42

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Anticonvulsants, folate levels, and pregnancy outcome: a prospective study

28 October 2022

43

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Serum folate concentrations during pregnancy in women with epilepsy: relation to antiepileptic drug concentrations, number of seizures, and fetal outcome.

28 October 2022

45

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Mammalian Epoxide Hydrases: Inducible Enzymes Catalysing the Inactivation of Carcinogenic and Cytotoxic Metabolites Derived from Aromatic and Olefinic Compounds

28 October 2022

47

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Distinct rat hepatic microsomal epoxide hydrolases catalyze the hydration of cholesterol 5,6 alpha-oxide and certain xenobiotic alkene and arene oxides

28 October 2022

49

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Complementary DNA and amino acid sequence of rat liver microsomal, xenobiotic epoxide hydrolase

28 October 2022

53

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Arene oxides: a new aspect of drug metabolism

28 October 2022

55

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Prenatal prediction of risk of the fetal hydantoin syndrome

28 October 2022

57

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

P450 genes: structure, evolution, and regulation

28 October 2022

59

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

P450 genes: evolution, regulation, and relationship to human cancer and pharmacogenetics

28 October 2022

61

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation

28 October 2022

63

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone

28 October 2022

65

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Hypotensive response to debrisoquine and hydroxylation phenotype

28 October 2022

66

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Reverse genetics and human disease

28 October 2022

69

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

A polymorphic DNA marker genetically linked to Huntington's disease

28 October 2022

70

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Genetic mapping of the human X chromosome by using restriction fragment length polymorphisms

28 October 2022

71

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

28 October 2022

74

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Molecular genetics of Duchenne and Becker muscular dystrophy

28 October 2022

75

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

28 October 2022

76

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Detection of specific sequences among DNA fragments separated by gel electrophoresis

28 October 2022

77

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Identification of the cystic fibrosis gene: genetic analysis

28 October 2022

78

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Mapping complex genetic traits in humans: new methods using a complete RFLP linkage map

28 October 2022

80

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Strategies for studying heterogeneous genetic traits in humans by using a linkage map of restriction fragment length polymorphisms

28 October 2022

81

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

Identification of the primary gene defect at the cytochrome P450 CYP2D locus

28 October 2022

82

1 reference

https://api.crossref.org/works/10.1177/106002809102500914

28 October 2022

Identifiers

0 references

1 reference